More studies are needed to identify the right dose, delivery method, formation, and intervention time.[3–5] Conventional medical treatments frequently fail to control pediatric UC, whereas the only approved biological treatments in children are infliximab and adalimumab, both of which are necrosis factor antagonistsα (anti-TNFα).[6] A significant proportion of children respond initially, then lose response or develop intolerant to anti-TNFα.[6] As a result, there is a significant unmet need for pediatric inflammatory bowel disease (IBD)for novel treatment. Here, TNF is linked to inflammatory bowel disease.